戻る Agendas
CHINESE REGULATORY SESSION: UPDATE FROM THE CFDA
Session Chair(s)
Ning Li, MD, PHD
Vice President, Head of Asia Regulatory and Medical Policy
Sanofi, China
Updates from two reports will be presented by the officials of Drug & Cosmetics Registration Dept. and the Center for Drug Evaluation of the China and Food Administration (CFDA). The progress of the ongoing Reform of Drug Review and Approval System and the encouragement of innovation, as well as the 2014 annual report of the drug technical review will be discussed.
Speaker(s)
CFDA’s Perspective on Clinical Trial Review for Drug Registration: Update from CDE/CFDA
Tao Wang, MD, PHD
China Food and Drug Administration (CFDA), China
Director of Chemical Medicine Evaluation office II
Issues and General Considerations of IND/CTA Applications in China
Haixue Wang
China Food and Drug Administration, China